News and Announcements
EPIAXIS THERAPEUTICS APPOINTS DR DARREN SAUNDERS AS CHIEF SCIENCE OFFICER
- Published April 21, 2022 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
EpiAxis Therapeutics has welcomed biomedical scientist Dr Darren Saunders as its new Chief Science Officer.
The appointment follows Dr Saunders joining EpiAxis Therapeutics in October 2021 as Science and Communications Advisor.
Dr Saunders is a research scientist specialising in cancer biology, Associate Professor in Medicine at the University of Sydney and Senior Research Advisor to Elizabeth Broderick and Co. He undertook post-doctoral training at the Garvan Institute and University of British Columbia and has held fellowships from the US Dept. of Defense and Cancer Institute NSW.
Dr Saunders has made significant contributions to leadership, governance and engagement through peak professional bodies and policy development. He is a regular commentator on television and radio, resident scientist on ABC TV’s The Drum and Channel 7’s Daily Edition, and 2019 Eureka Prize winner.
“We are delighted that a scientist and skilled communicator of Dr Saunders’ calibre has chosen to join EpiAxis as its Chief Science Officer,” EpiAxis Therapeutics CEO Dr Jeremy Chrisp said. “His appointment is another significant step in the development of our Company as we continue to progress our epigenetic pipeline.”
Dr Saunders said he was excited to expand his role with EpiAxis Therapeutics during its mission to reprogram cancer and immune cells with next generation therapeutics.
“I’m excited to be joining EpiAxis at an important time for the company,” he said. “I’m really looking forward to advancing the development of new therapeutic strategies for cancer in the rapidly evolving epigenetic space.”
ABOUT EPIAXIS THERAPEUTICS:
EpiAxis is a leading drug development company that aims to make cancer a chronic disease rather than a fatal one, by using epigenetic science to create a completely different approach to cancer treatment. Our therapies work differently to existing – and often toxic – treatments by uniquely reprogramming the cancer cells back towards normal cells.
Company Updates
The System’s Immune System: Why Big Tech Will Solve What Big Pharma Can’t
The central investment thesis for the future of human health pits Big Pharma against Big Tech. This blog post explores the “Protocol Paradox” in current cancer care and argues that the convergence of hyperscalers and life-science experts—treating biology as a data and compute problem—represents the defining compounding investment opportunity of this era.
The Life Sciences Supercycle: Why Australian Biotech is Finally Delivering Billion-Dollar Outcomes
Australia’s life sciences sector is experiencing an unprecedented “Supercycle,” finally commercializing world-class research into global, billion-dollar businesses. Learn about the ASX heavyweights, the key drivers (AI, institutional execution, FDA pathway), and the investment opportunity at Emergence 2026.
Following the Billions: Where the Hyperscalers are Betting on the Future
The roadmap for the next decade isn’t hidden in pitch decks—it’s written on the balance sheets of Microsoft, Amazon, and Google. Their collective investment is flowing into three key areas: GPU Chips, AI Factories, and Energy. This foundational buildout signals a $7–$20 trillion economic convergence, where the physical race for infrastructure and energy is paramount. The article also covers the powerful macro case for digital assets in this new era.
Backed By Leading Investment Groups and Family Offices
